Combination therapy with flupirtine and opioid: Studies in rat pain models

Pain Medicine

Volumn 9, Issue 7, 2008, Pages 928-938

  Goodchild, Colin S ^a,b,c   Kolosov, Anton ^a   Tucker, Adam P ^a   Cooke, Ian ^b  

^a MONASH UNIVERSITY   (Australia)

^b CNSBio Ltd Pty Ltd   (Australia)

^c NONE   (Australia)

Author keywords

Animal Models; Antinociception; Carrageenan; Diabetes; Flupirtine; Inflammation; Morphine; Neuropathic Pain; Streptozotocin

Indexed keywords

FLUPIRTINE; MORPHINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CARRAGEENAN PAW INFLAMMATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TREATMENT FAILURE; INFLAMMATION; LOW DRUG DOSE; MONOTHERAPY; NEUROPATHIC PAIN; NONHUMAN; RAT; SEDATION; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; WISTAR RAT;

AMINOPYRIDINES; ANALGESICS; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MALE; MORPHINE; NEURALGIA; PAIN MEASUREMENT; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 52949140582     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2008.00514.x     Document Type: Article

References (31)

1. Yang WP, Levesque PC, Little WA, etal. Functional expression of two KvLQT1-related potassium channels responsible for an inherited idiopathic epilepsy. J Biol Chem 1998;273(31):19419-23.
2. Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone. Nature 1980;283(5748):673-6.
3. Marrion NV. Control of M-current. Annu Rev Physiol 1997;59:483-504.
4. Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003;7(6):737-48.
5. Martire M, Castaldo P, D'Amico M, et al. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 2004;24(3):592-7.
6. Bleyer H, Carlsson KH, Erkel HJ, Jurna I. Flupirtine depresses nociceptive activity evoked in rat thalamus. Eur J Pharmacol 1988;151:259-65.
7. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45(4):548-69.
8. Schwarz M, Block F, Pergande G. N-methyl-D-aspartate (NMDA)-mediated muscle relaxant action of flupirtine in rats. Neuroreport 1994;5:1981-4.
9. 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995;276:247-55.
10. Osborne NN, Pergande G, Block F, Schwarz M. Immunohistochemical evidence for flupirtine acting as an antagonist on the N-methyl-D-aspartate and homocysteic acid- induced release of GABA in the rabbit retina. Brain Res 1994;667:291-4.
11. Kornhuber J, Bleich S, Wiltfang J, Maler M, Parsons CG. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 1999;106(9,10):857-67.
12. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16(2):109-10.
13. Cartmell SM, Gelgor L, Mitchell D. A revised rotarod procedure for measuring the effect of antinociceptive drugs on motor function in the rat. J Pharmacol Methods 1991;26:149-59.
14. Courteix C, Eschalier A, Lavarenne J. Streptozocin-induced diabetic rats: Behavioural evidence for a model of chronic pain. Pain 1993;53:81-8.
15. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 1994;57(2):153-60.
16. Randall LO, Selitto JJ. A method for measurement of analgesic activity of inflamed tissue. Archiv Int Pharmacdynamie 1957;111:409.
17. Max MB. Towards physiologically based treatment of patients with neuropathic pain. Pain 1990;42:131-3.
18. Max MB. U.S. government disseminates acute pain treatment guidelines: Will they make a difference? Pain 1992;50:3-4.
19. Sindrup SH, Gram LF, Brosen K, Eshoj O, Mogensen EF. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42(2):135-44.
20. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain [see comments]. Pain 1988;33(1):11-23.
21. Avidan A, Devor M. 1995 intravenous lidocaine infusion for chronic pain therapy. Isr J Med Sci 1996;32:331-4.
22. Davis BL, Manzanares J, Lookingland KJ, Moore KE, Clemens LG. Noradrenergic innervation to the VMN or MPN is not necessary for lordosis. Pharmacol Biochem Behav 1991;39:737-42.
23. Galer BS. Neuropathic pain of peripheral origin: Advances in pharmacologic treatment. Neurology 1995;45(suppl9):S17-25.
24. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003;105(1-2):71-8.
25. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions [see comments]. Pain 1990;43(3):273-86.
26. Kumbhat S, Meyer N, Schurr MJ. Complex regional pain syndrome as a complication of a chemical burn to the foot. J Burn Care Rehabil 2004;25(2):189-91.
27. Pavelka K. Symptomatic treatment of osteoarthritis:pAracetamol or NSAIDs? Int J Clin Pract Suppl 2004;144:5-12.
28. Portenoy RK. Adjuvant analgesic agents. Hematol Oncol Clin North Am 1996;10:103-19.
29. Shang AB, Gan TJ. Optimising postoperative pain management in the ambulatory patient. Drugs 2007;63(9):855-67.
30. Passmore GM, Selyanko AA, Mistry M, et al. KCNQ/M currents in sensory neurons: Significance for pain therapy. J Neurosci 2003;23(18):7227-36.
31. Portenoy RK, Foley KM, Inturrisi CE. Genuine resistance to opioids-fact or fiction? Response. Pain 1991;47:119-21.